Stockscreener 앱 받기
106.65
0.15%
0.16
시간 외 거래:
106.71
0.06
+0.06%
전일 마감가:
$106.49
열려 있는:
$106.49
하루 거래량:
640.57K
Relative Volume:
0.53
시가총액:
$9.40B
수익:
$688.00K
순이익/손실:
$-168.74M
주가수익비율:
-45.23
EPS:
-2.3577
순현금흐름:
$-185.87M
1주 성능:
+1.96%
1개월 성능:
+4.43%
6개월 성능:
+145.45%
1년 성능:
+513.64%
1일 변동 폭
$104.94
$108.02
1주일 범위
$101.44
$110.17
52주 변동 폭
$14.51
$110.17
Spyre Therapeutics Inc Stock (SYRE) Company Profile
명칭
Spyre Therapeutics Inc
전화
(617) 651-5940
주소
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
106.65 | 9.50B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Raymond James | Strong Buy |
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-12-17 | 개시 | Citigroup | Buy |
| 2025-09-26 | 개시 | Deutsche Bank | Buy |
| 2025-04-08 | 개시 | Leerink Partners | Outperform |
| 2025-03-18 | 개시 | Wolfe Research | Outperform |
| 2024-09-04 | 개시 | Wedbush | Outperform |
| 2024-07-16 | 개시 | Evercore ISI | Outperform |
| 2024-05-02 | 개시 | Robert W. Baird | Outperform |
| 2024-03-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-12-11 | 개시 | Guggenheim | Buy |
| 2023-12-11 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2019-03-21 | 개시 | JP Morgan | Overweight |
| 2018-09-04 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 개시 | Evercore ISI | Outperform |
| 2018-03-14 | 재확인 | Needham | Buy |
모두보기
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
RTW Investments, LP Expands Spyre Therapeutics (SYRE) Stake With Strategic Add - GuruFocus
Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch? - simplywall.st
This Stock’s Already Up Nearly 600% Over the Past Year - Yahoo Finance
Price to book forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE - TradingView
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week HighHere's What Happened - MarketBeat
Spyre Therapeutics stock hits 52-week high at 108.16 USD - Investing.com
Spyre Therapeutics (SYRE) Edges Higher at $104.60: Consolidation Builds Ahead of Resistance TestCall Wall - Vinanet
Handelsbanken Fonder AB Makes New $2.31 Million Investment in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Wall Street Zen Downgrades Spyre Therapeutics (NASDAQ:SYRE) to Sell - MarketBeat
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123 - Moomoo
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $129 - Moomoo
Perceptive Advisors discloses 4.9% stake in Spyre Therapeutics (SYRE) via Master Fund - Stock Titan
RTW Investments (SYRE) reports 4.8% Spyre Therapeutics stake for managed funds - Stock Titan
Dimensional Fund Advisors LP Sells 29,593 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $126.85, Implies 22% Upside - TradingView
Spyre Therapeutics (SYRE) Pulls Back 2.46% as Bulls Defend $97.6 SupportVol Target Rebalance - Vinanet
Price to earnings forward of Spyre Therapeutics, Inc – SWB:3920 - TradingView
Price to book forward of Spyre Therapeutics, Inc – SWB:3920 - TradingView
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
SYRE Maintained by BTIG -- Price Target Raised to $132.00 - GuruFocus
Spyre Therapeutics director Jeffrey W. Albers disposes of USD 2.39 million in common shares - Bitget
Spyre Therapeutics, Inc. $SYRE Shares Bought by Bank of America Corp DE - MarketBeat
Spyre Therapeutics Insider Sold Shares Worth $2,404,190, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics director Albers sells $2.4m in stock By Investing.com - Investing.com India
Spyre Therapeutics director Albers sells $2.4m in stock - Investing.com India
Spyre Therapeutics (NASDAQ:SYRE) Director Sells 18,000 Shares - MarketBeat
Spyre Therapeutics (SYRE) director logs 5,000-share option exercise and 23,000-share sale - Stock Titan
Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa - marketscreener.com
Spyre Therapeutics Announces Launch Of Spy772 Program - TradingView
Spyre Therapeutics launches combination therapy trial for hidradenitis suppurativa - Investing.com
Spyre Therapeutics launches combination therapy trial for hidradenitis suppurativa By Investing.com - Investing.com Nigeria
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa - The Manila Times
Spyre Therapeutics, Inc. Launches SPY772 Program And Initiates Phase 2 SKYLIGHT Trial In Hidradenitis Suppurativa - marketscreener.com
California State Teachers Retirement System Purchases 11,204 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Can Spyre Therapeutics (SYRE) Justify Its Premium After Positive Phase 2 Data? - Yahoo Finance
Price to sales forward of Spyre Therapeutics, Inc. – NASDAQ:SYRE - TradingView
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128 - Moomoo
Spyre Therapeutics (NASDAQ:SYRE) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Spyre Therapeutics, Inc. SEC Filing (Aug 7, 2026) - Stock Titan
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics, Inc. (SYRE) Investor Outlook: Promising Biotech with 4.98% Upside Potential - directorstalkinterviews.com
Price to earnings forward of Spyre Therapeutics, Inc – DUS:3920 - TradingView
Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know - The Motley Fool
A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know - The Motley Fool
SPYRE THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $121 FROM $88 - webull.com
We Think Spyre Therapeutics (NASDAQ:SYRE) Can Easily Afford To Drive Business Growth - Moomoo
Cameron Turtle, Spyre Therapeutics CEO, sells $1.43m in stock By Investing.com - Investing.com South Africa
Spyre CFO Scott Burrows sells $716,771 in stock By Investing.com - Investing.com Nigeria
Form 4 Spyre Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Spyre Therapeutics Inc (SYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
3.22%
자본화:
|
볼륨(24시간):